On Wednesday, Patient Square Capital, a healthcare investment firm, agreed to acquire Patterson Companies, Inc. (NASDAQ:PDCO), a dental and animal health product distributor, for approximately $4.1 billion.
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger, to boost shareholder value.
William Blair notes that based on Patient Square Capital’s portfolio, which doesn’t include dental or animal health companies, regulatory hurdles for this deal are unlikely.
Additionally, the analyst’s dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
The valuation analysis includes Align Technology Inc (NASDAQ:ALGN), Dentsply Sirona Inc (NASDAQ:XRAY), Henry Schein Inc (NASDAQ:HSIC), Envista Holdings Corporation (NYSE:NVST) and Europe-listed Straumann Holding.
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
Most recently, Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary suspension of sales, marketing, and shipments of Byte Aligners and Impression Kits.
Henry Schein’s third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) to $1.1 billion.
While it’s still early to gauge investor reactions, the analyst is considering whether Patterson’s acquisition might stabilize valuations and boost demand in the dental sector.
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
Read Next:
Photo via Shutterstock
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | |
Jan 2022 | Morgan Stanley | Initiates Coverage On | Equal-Weight | |
Jun 2021 | Piper Sandler | Upgrades | Neutral | Overweight |
View More Analyst Ratings for PDCO
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players? originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.